financetom
Business
financetom
/
Business
/
Semiconductor parts maker Aixtron secures solid Q3 orders despite core profit miss
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Semiconductor parts maker Aixtron secures solid Q3 orders despite core profit miss
Oct 31, 2024 2:41 AM

Oct 31 (Reuters) - Aixtron reported on

Thursday a strong order intake for the third quarter, even as

the German chip systems manufacturer's quarterly core profit

missed market expectations.

The company, which supplies deposition equipment for

chipmakers, said its order intake was 143.5 million euros ($156

million), up 21% from 118.5 million euros a year earlier.

The group's earnings before interest and taxes (EBIT) fell

17% year-on-year to 37.5 million euros in the quarter, missing

analysts' average estimate of 42.7 million euros in a

company-provided poll.

Chip stocks have been under pressure after the U.S.

government's tighter restrictions on exports of chip equipment

to China and uncertainty over the U.S. presidential election

made investors cautious. Weak demand for automotive, personal

computer and memory chips has been only partially offset by

increased demand for AI chips.

"Order intake in Q3 of 143.5 million is down vs the Q2 level

of 176 million euros. The sequential drop is expected, it is

below consensus of 159 million euros but we believe still solid

in the current weak environment," Stifel analyst Juergen Wagner

said in a note.

"We believe this explicit and early guidance for next year

should be taken well by the market, which has been cutting FY25

consensus in recent weeks given ongoing weakness in the electric

vehicle (EV) and silicon carbide (SiC) market," analysts from

Jefferies said in a note.

They continue to believe Aixtron is well-positioned for an

eventual recovery in the silicon carbide market due to its

leading market share.

Aixtron said that it expects 2025 revenue near the level of

fiscal year 2024 or slightly below.

"We see this release as better than some could have feared

and 2025 revenue comments did not come as a surprise for us,"

analyst Martin Marandon-Carlhian at ODDO BHF told Reuters.

The company also confirmed its full-year guidance for 2024,

expecting revenue to be in a range of 620 million to 660 million

euros.

($1 = 0.9212 euros)

(Reporting by Ozan Ergenay, editing by Thomas Escritt and

Emelia Sithole-Matarise)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Copyright 2023-2025 - www.financetom.com All Rights Reserved